Enveric Biosciences (NASDAQ:ENVB) Posts Quarterly Earnings Results, Beats Estimates By $55.30 EPS

Enveric Biosciences (NASDAQ:ENVB) issued its quarterly earnings results on Friday. The company reported ($0.50) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($55.80) by $55.30, FiscalAI reports.

Enveric Biosciences Trading Up 1.1%

ENVB stock traded up $0.02 during mid-day trading on Friday, reaching $1.88. The company’s stock had a trading volume of 47,422 shares, compared to its average volume of 371,763. The company’s 50 day moving average is $2.54 and its two-hundred day moving average is $5.21. Enveric Biosciences has a fifty-two week low of $1.82 and a fifty-two week high of $19.20. The stock has a market cap of $2.61 million, a PE ratio of -0.05 and a beta of 0.31.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Enveric Biosciences in a report on Thursday, January 22nd. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Enveric Biosciences has an average rating of “Sell”.

Enveric Biosciences Company Profile

Enveric Biosciences is a clinical-stage biopharmaceutical company focused on the discovery and development of novel psychedelic-based therapeutics for the treatment of psychiatric and neurological disorders. The company’s research platform leverages proprietary medicinal chemistry to design, synthesize and optimize molecules derived from established psychoactive compounds, with a goal of improving safety, efficacy and tolerability compared with traditional formulations.

Enveric’s preclinical pipeline features synthetic analogs of ibogaine, psilocybin and MDMA, each engineered to enhance therapeutic outcomes in conditions such as post-traumatic stress disorder, major depressive disorder and anxiety.